A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Pfizer
Eli Lilly and Company
Bristol-Myers Squibb
Arcus Biosciences, Inc.
Pfizer
Pfizer
AstraZeneca
M.D. Anderson Cancer Center
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Canadian Cancer Trials Group
Gilead Sciences
National Institutes of Health Clinical Center (CC)